Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of drug development programs. This article highlights unique expertise, tools and other attributes that can help companies excel in oncology clinical trials.

Covance Central Laboratory Services Experience Metrics for Rheumatoid Arthritis

In the field of immuno-oncology, the heterogeneity of patient responses to treatments is well documented and can play an important role in determining the clinical benefits of new therapies.

AACC 2017 -- Alzheimer's disease (AD) is the most common neurodegenerative disorder and is a major health problem among older people. Synaptic dysfunction and loss are directly linked to memory disturbances and other cognitive symptoms that are present at the early stages of AD.

Number of cardiovascular/metabolic studies performed in Central Laboratory Services

The field of biosimilars is expanding rapidly. They provide an opportunity for cost savings for key stakeholders, and for pharmaceutical and biotech companies to control a share of the market as the patents for blockbuster biologic drugs expire.

A large, global pharmaceutical client has formed a strategic alliance with Covance for complete biometrics services.

Covance Central Laboratory Services supported all of the top 10 asthma and COPD best-selling drugs of 2016.

This white paper considers the recent paradigm shifts in oncology drug development and explores the current requirements of early-phase oncology trials.